Every story in this section, newest first — page 60 of 373.
Johnson & Johnson (NYSE:JNJ) reported final Phase 3 PAPILLON results showing median overall survival of 34.3 months with first-line IV RYBREVANT plus carboplatin-pemetrexed versus 27.9 months with chemotherapy alone.
AstraZeneca (NASDAQ:AZN) reported updated Phase III ADAURA results showing TAGRISSO reduced the risk of death by 48% versus placebo after eight years in the overall Stage IB-IIIA EGFR-mutated NSCLC population.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo reported that ENHERTU achieved median progression-free survival of 14.3 months in the Phase III DESTINY-Lung04 lung cancer trial.
Nanobiotix (NASDAQ:NBTX) reported complete Phase 1 full-cohort results for radiotherapy-activated JNJ-1900, formerly NBTXR3, in 24 patients with inoperable, locoregionally recurrent non-small cell lung cancer eligible for re-irradiation.
Takeda (NYSE:TAK) said the U.S. FDA accepted its New Drug Application for zasocitinib under Priority Review for adults with moderate-to-severe plaque psoriasis.
Novo Nordisk (NYSE:NVO) launched a corporate rebrand that will see the company use the shorter “Novo” name in day-to-day communications while retaining Novo Nordisk A/S as its legal name.
Clearmind Medicine (NASDAQ:CMND) enrolled the first two patients with Alcohol Use Disorder in its ongoing clinical trial of CMND-100, a non-hallucinogenic psychedelic-derived drug candidate.
Virtus Investment Partners (NYSE:VRTS) reported preliminary assets under management of $147.5 billion and other fee-earning assets of $1.7 billion as of August 31, 2026.
Victory Capital (NASDAQ:VCTR) reported total assets under management of $356.5 billion as of August 31, 2026, with total client assets reaching $360.2 billion.
Rent the Runway (NASDAQ:RENT) reported fiscal second-quarter 2026 revenue of $97.7 million, up 20.8% year over year, while narrowing its net loss and improving profitability.
Olin (NYSE:OLN) and Huntsman (NYSE:HUN) announced that the waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act for their proposed merger of equals has expired.
Eloxx Pharmaceuticals (NASDAQ:ELOX) dosed the first two patients in the EXACT Study, a Phase 2b clinical trial evaluating exaluren in patients with nonsense mutation Alport syndrome.
Public Policy Holding Company (NYSE:PPHC) declared a 2026 interim dividend of $0.117 per share, representing a 2% increase from the prior-year interim dividend after adjusting for the previous share consolidation.
NRx Pharmaceuticals (NASDAQ:NRXP) announced that its subsidiary HOPE Therapeutics has started deploying Zeta Surgical’s FDA-cleared robotic TMS system at Florida clinics.
Kroger (NYSE:KR) reported second-quarter 2026 sales of $34.6 billion and adjusted earnings per share of $1.09 for the quarter ended August 15, 2026.
Citi Trends (NASDAQ:CTRN) announced that Chief Financial Officer Heather Plutino has decided to step down from her role for personal reasons.
Invitation Homes (NYSE:INVH) declared a quarterly cash dividend of $0.30 per share on its common stock.
Lazard (NYSE:LAZ) reported preliminary assets under management of $290.3 billion as of August 31, 2026, up from $286.9 billion at the end of July.
VinFast (NASDAQ:VFS) reported preliminary domestic Vietnam deliveries of 20,161 electric vehicles in August 2026, representing a 12% increase from the previous month.
Bausch + Lomb (NYSE:BLCO) received European CE Mark approval for SeeLyra, a next-generation femtosecond laser platform designed for ophthalmic surgical procedures.
SFL Corporation (NYSE:SFL) agreed to extend charter contracts for six 15,400 TEU container vessels with Hapag-Lloyd AG for an additional seven years.
MoneyHero Group (NASDAQ:MNY) reported second-quarter 2026 revenue of US$15.8 million, down 13% year over year, with a net loss of US$1.2 million.
Perspective Therapeutics (NYSE:CATX) announced that updated data from its [212Pb]VMT-α-NET program have been accepted for presentation at the 38th EORTC-NCI-AACR Symposium in Barcelona.
Hooker Furnishings (NASDAQ:HOFT) reported a profitable second quarter of fiscal 2027, with net income reaching $1.7 million after benefiting from tariff recoveries and previous cost reductions.
